FDA’s Gottlieb launches biosimilars action plan

The US Food and Drug Administration (FDA) is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FDA chief Gottlieb resigns after nearly two years

6 March 2019 Scott Gottlieb, commissioner of the US Food and Drug Administration, resigned from his post yesterday, March 5, with plans to step down in the next month.

Americas

FDA improves generic approval rate under Trump: report

26 October 2018 The US Food and Drug Administration’s generic drug approval rate has increased at a “rapid rate” since January 2017, despite the number of branded drug patent expirations declining during this period.

Americas

FDA issues guidance on generic versions of complex drugs

11 October 2018 The US Food and Drug Administration has released guidance intended to advance the development of generic versions of complex medical drugs.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

FDA’s Gottlieb launches biosimilars action plan

More on this story

Editor's picks

Editor's picks

More features